If you are 60+, live in Sydney, ROSEND needs you

Written by on December 9, 2023 in clinical trials, Off Label Treatments, research with 0 Comments

A just listed trial in Sydney is looking for 40 over sixty year olds to evaluate a possible new treatment for rosacea – Volumetric Modulated Arc Therapy (VMAT). VMAT is a type of radiotherapy that is normally used to treat skin cancer. The trial, named ROSEND, wants to see if VMAT might offer a benefit for rosacea sufferers who have not had success with current treatments.

According to the clinical trial site, researchers are looking for patients who are at least 60 years old, have rosacea for at least 10 years and have tried at least one topical and one systemic rosacea treatment. Three locations in greater Sydney are wanting to recruit patients – Revesby, Gosford and Wahroonga.

Australian New Zealand Clinical Trials Registry

ACTRN12622001585718

The ROSEND Trial – A Randomised trial for the treatment of recalcitrant symptomatic rosacea using definitive volumetric modulated arc radiotherapy or standard dermatological treatment.

ARM B: Volumetric Modulated Arc Therapy (VMAT): 36Gy in 20 once daily fractions delivered within a period of eight weeks in total inclusive of a mid-treatment break of a minimum two weeks.

Patients are required to attend a treatment planning session that will assist with planning the treatment. The planning procedure will take up to approximately 60 minutes and involve a computed-tomography (CT) scan with the patient positioned in the treatment position.

Treatment is expected to take around 15 minutes per treatment. The intervention will be prescribed by a radiation oncologist and administered by radiation therapists. Patients will commence treatment within four (4) weeks or randomisation and there will be approximately one (1) to two (2) weeks from the time of simulation to the commencement of radiotherapy.

During treatment, imaging will be completed to ensure treatment is administered accurately.

The VMAT treatment is 20 treatments given as 10 treatments over two weeks, then a two-week break, and then another ten treatments over two weeks. Each treatment involves 15 minutes in the treatment room. There is no pain during treatment and so no anaesthetic is required. The trial does involve some biopsies. Trial participants will be randomised by computer to either VMAT or to dermatology best practice.

Some research that supports the proposal that VMAT may offer hope to recalcitrant rosacea can be found here: Incidental Long Term Control of Recalcitrant Rosacea Following Modern Radiotherapy – A Case Series

Please see the trial listing for more information and contact details of Gerald Fogarty if you are interested in joining the trial.

About the Author

About the Author: David Pascoe started the Rosacea Support Group in October 1998. .

Follow Rosacea Support

Subscribe via RSS Feed

Leave your comment here

Top

Subscribe to Rosacea News

Enter your email address to receive the latest news about rosacea in your inbox.